ATTO Stock — Attovia Therapeutics Inc.: Cash, EV, Pipeline

Share price

$22.14

Market cap

$1,010.7M

Cash

$380.2M

Enterprise value

$630.5M

Balance sheet

Cash	$380.2M
Debt	$0.0M
Net cash	$380.2M
Enterprise value	$630.5M
Basic shares	4.5M shares
Fully diluted shares	48.7M shares
Fully diluted market cap	$1,078.7M
Cash per share	$84.49

Cash figures as of 2026-08-06. Database snapshot: 2026-09-21.

Price history

Loading ATTO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 26 - Oct 7	ATTO-1091	Phase 1	Ulcerative Colitis (UC)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ATTO-1310

Stage not disclosed · Active

Target IL-31

Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.

ATTO-2306

Stage not disclosed · Active

Target IL-13/IL-31

Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.

ATTO-1091

Stage not disclosed · Active

Target TL1A/IL-23/α4β7

Indications

Ulcerative Colitis (UC) (Phase 1)

Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.

Per-asset detail extracted from the 10-Q filed 2026-09-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ATTO-1091
Lead indication	Ulcerative Colitis (UC)
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07819799	Phase 1	Not yet recruiting	Sponsor	ATTO	—	Ulcerative Colitis (UC)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Attovia Therapeutics Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ATTO — Attovia Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials